<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02021136</url>
  </required_header>
  <id_info>
    <org_study_id>2013-A00613-42</org_study_id>
    <secondary_id>2013-A00613-42</secondary_id>
    <nct_id>NCT02021136</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Rebel Reliever Brace in Patients With Symptomatic Medial Knee Osteoarthritis</brief_title>
  <acronym>ROTOR</acronym>
  <official_title>Efficacy and Safety of Rebel Reliever Brace in Medial Femorotibial Knee Osteoarthritis. Phase 3, Multicenters, Randomised and Controlled Study With 2 Parallel Groups.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thuasne</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thuasne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the superiority of Rebel RelieverÂ® knee brace +
      standard treatment versus standard treatment alone in terms of last 24-hour pain relief after
      6 weeks. in patients with medial knee osteoarthritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main criteria is the evaluation of global knee pain during the last 24 hours at D 49
      after the inclusion.

      The response to the treatment will be evaluated during the inclusion visit (V1/D0) and after
      6 weeks of treatment, during the following visit (V3/D49).

      The level of the global pain of the patient during the last 24 hours will be collected by
      investigators with a VAS (0 mm = no pain ; 100mm = maximun pain) at each visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evolution of the last 24 hours knee pain (VAS)</measure>
    <time_frame>Between Day 49 and Day 0</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evolution of knee pain on movement (VAS)</measure>
    <time_frame>Between Day 49 and Day 0</time_frame>
    <description>Evaluation with Visual Analysis Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of Lequesne Algofunctional index score</measure>
    <time_frame>Between D49 and Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder rate according to OARSI-OMERACT criteria</measure>
    <time_frame>At Day 49</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of patients with at least one adverse event or serious adverse event in each groups.</measure>
    <time_frame>during the 6 weeks of brace wearing</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Rebel reliever</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rebel Reliever(R) knee brace + usual antalgic treatment + physical exercises recommendations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>usual antalgic treatment + physical exercises recommendations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Rebel Reliever</intervention_name>
    <description>Rebel Reliever knee brace + usual antalgic treatment + physical exercises recommendations</description>
    <arm_group_label>Rebel reliever</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Usual antalgic treatment + physical exercises recommendations</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Male or female over 18 years

          -  BMI &lt; or egal to 35kg/m2

          -  symptomatic gonarthrose defined by a recurrent pain to the walk on 30 days during the
             last 2 months before the inclusion with radiological findings (grade II to IV on
             Kellgren-Lawrence)

          -  diagnosis of medial femoro-tibial knee osteoarthrosis

          -  patient with global pain intensity during the last 24hours &gt; or egal 40 mm (EVA) at
             the day of selection

        Main Exclusion Criteria:

          -  femoro-patellar predominant arthrosis

          -  septic arthritis

          -  metabolic arthropathies

          -  chronical rheumatismal diseases

          -  other knee diseases

          -  symptomatic coxarthrosis

          -  controlateral gonathrosis with corticoids injections

          -  any other serious disease which may interfere with the results

          -  psychiatrics disorders

          -  skin lesions or dermal pathologies

          -  venous or arterial disorders

          -  sensitivity disorders in the lower limbs (diabetes mellitus..)

          -  paracetamol intolerance

          -  hyaluronic acid or corticosteroid intra-articular injection in the last month prior to
             inclusion

          -  on going knee viscosupplementation at inclusion

          -  slow acting OA drugs (if started in the last 2 months prior to inclusion)

          -  opioids, corticosteroids, or NSAIDs intake in the last 48 hours prior to inclusion

          -  pregnant women of with no contraception

          -  hepatic or renal insufficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe THOUMIE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Coordinator</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Euraxi Pharma</name>
      <address>
        <city>Joue-les-tours</city>
        <state>Bp 80325</state>
        <zip>37303</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2013</study_first_submitted>
  <study_first_submitted_qc>December 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 27, 2013</study_first_posted>
  <last_update_submitted>December 29, 2016</last_update_submitted>
  <last_update_submitted_qc>December 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

